These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25891346)

  • 21. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
    Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
    Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
    Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
    Duvic M; Bates SE; Piekarz R; Eisch R; Kim YH; Lerner A; Robak T; Samtsov A; Becker JC; McCulloch W; Waksman J; Whittaker S
    Leuk Lymphoma; 2018 Apr; 59(4):880-887. PubMed ID: 28853310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.
    Kim EJ; Kim YH; Rook AH; Lerner A; Duvic M; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Waksman J; Whittaker S
    Leuk Lymphoma; 2015; 56(10):2847-54. PubMed ID: 25791237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
    Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA
    Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Romidepsin for the treatment of cutaneous T-cell lymphoma.
    Campas-Moya C
    Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Romidepsin Therapy Over 5 Years in a Clinical Setting-Real-world Experience.
    Bates SE; Geskin LJ
    JAMA Oncol; 2016 Jun; 2(6):794-5. PubMed ID: 27054784
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.
    Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S
    Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
    Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S
    Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
    Hronek J; Reed M
    Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
    J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
    Ritchie D; Piekarz RL; Blombery P; Karai LJ; Pittaluga S; Jaffe ES; Raffeld M; Janik JE; Prince HM; Bates SE
    Haematologica; 2009 Nov; 94(11):1618-22. PubMed ID: 19608677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romidepsin in the treatment of T-cell lymphoma: profile report.
    Yang LP
    BioDrugs; 2011 Dec; 25(6):393-5. PubMed ID: 22050341
    [No Abstract]   [Full Text] [Related]  

  • 39. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
    Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
    J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romidepsin (Istodax) for cutaneous T-cell lymphoma.
    Med Lett Drugs Ther; 2010 May; 52(1339):42-3. PubMed ID: 20508581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.